Remove Clinical Development Remove Medicine Remove Research Remove Trials
article thumbnail

Why Should Companies Use Digital Endpoints Across Clinical Development?

XTalks

The traditional clinical trials model is facing scrutiny. VivoSense , a pioneering company in the field of digital health technologies (DHTs) and digital endpoints for clinical trials, is aiming to enhance the efficiency and efficacy of clinical research.

article thumbnail

Gemini enters business combination deal with Disc Medicine

Pharmaceutical Technology

Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US.

Medicine 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RVAC Medicines, A*STAR partner for mRNA manufacturing expertise

Pharmaceutical Technology

RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore.

article thumbnail

The Power of Personalization Amid the Changing CRO Landscape

Worldwide Clinical Trials

Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. What Differentiates Mid-Size CROs?

article thumbnail

Bridging Gaps in Rare Disease Clinical Trials: Insights from Collaborative Success in Pompe Disease Research

XTalks

Participant recruitment is challenging, especially in those indications in which there are competing clinical trials necessitating a comprehensive understanding of the disease research ‘landscape’ and targeted outreach and stakeholder collaboration.

article thumbnail

Cell and gene therapies: why advanced medicines call for specialised logistics

Pharmaceutical Technology

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. A new frontier in cancer research. It is certainly a pivotal moment for the cell and gene industry, with the next decade of R&D and clinical trials expected to transform the future of medicine.

article thumbnail

Rezvilutamide by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100